TrialThe Lancet. Oncology2022

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

Michael L Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.